BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28094372)

  • 1. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
    Liang D; Chen Q; Guo Y; Zhang T; Guo W
    Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
    Pan YL; Liu YL; Chen JZ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of the human fibroblast growth factor receptor 4 kinase.
    Lesca E; Lammens A; Huber R; Augustin M
    J Mol Biol; 2014 Nov; 426(22):3744-3756. PubMed ID: 25219510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.
    Yosaatmadja Y; Patterson AV; Smaill JB; Squire CJ
    Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):525-33. PubMed ID: 25760602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
    Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
    PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
    Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
    Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptors 1 and 4 combined with lymph node metastasis predicts poor prognosis in oral cancer.
    Gu ZY; Zhou R; Hong D; Han Y; Wang LZ; Li J; Zhang ZY; Shi CJ
    Oral Dis; 2024 Apr; 30(3):1004-1017. PubMed ID: 36938639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
    Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3.
    Hwang G; Kim H; Yoon H; Song C; Lim DK; Sim T; Lee J
    Int J Nanomedicine; 2017; 12():5345-5357. PubMed ID: 28794627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
    Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
    Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
    Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
    Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
    Ryan MR; Sohl CD; Luo B; Anderson KS
    Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.